Atara Biotherapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Atara Biotherapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Atara Biotherapeutics Inc Strategy Report
- Understand Atara Biotherapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Atara Biotherapeutics Inc (Atara) is a biopharmaceutical company specialized in T-cell immunotherapy. The company uses its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for the treatment of cancers, other autoimmune diseases, and severe viral infections. It is evaluating its lead candidate, tabelecleucel in Phase III clinical trials for the treatment of Epstein Barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD) following hematopoietic cell transplant and solid organ transplant in patients who refracted rituximab. Its pipeline product candidates that are being developed for multiple indications in various stages of clinical trials include ATA188, ATA2271, ATA3219, ATA3271 and other CAR T programs. Atara is headquartered in South San Francisco, California, the US.
Headquarters
United States of America
Address
2380 Conejo Spectrum St, Suite 200, Thousand Oaks, California, 91320
Website
www.atarabio.com
Telephone
1 805 6234244
No of Employees
225
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ATRA (NASD)
Revenue (2022)
$8.6M
-86.5%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-20.9%
(2022 vs 2021)
Market Cap*
$84.5M
Net Profit Margin (2022)
XYZ
-796.9%
(2022 vs 2021)
* As of and is in US$
Atara Biotherapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Product Pipeline:- | - |
| Tab-cel, or Tabelecleucel: | Tab-cel |
| RR EBV+ PTLD following HCT | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Divestiture | In November, the company sold its marketing rights to Ebvallo (tabelecleucel) in North America, Asia Pacific, and Latin America to Pierre Fabre Laboratories. |
| 2022 | Contracts/Agreements | In December, the company entered into a royalty interest financing agreement worth US$31 million with HealthCare Royalty for Ebvallo in Europe and other territories covered by Atara’s commercialization agreement with Pierre Fabre. |
| 2022 | Regulatory Approval | In December, the company secured approval from the European Commission for marketing authorization of Ebvallo (tabelecleucel) as a monotherapy to treat Epstein‑Barr virus positive post‑transplant lymphoproliferative disease (EBV+ PTLD) patients. |
Competitor Comparison
| Key Parameters | Atara Biotherapeutics Inc | F. Hoffmann-La Roche Ltd | Sanofi | Novartis AG | Bristol-Myers Squibb Co |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | France | Switzerland | United States of America |
| City | Thousand Oaks | Basel | Paris | Basel | Princeton |
| State/Province | California | - | Ile-de-France | - | New Jersey |
| No. of Employees | 225 | 103,605 | 87,994 | 76,057 | 34,100 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Carol Gallagher | Chairman | Executive Board | 2022 | 58 |
| Pascal Touchon | Chief Executive Officer; Director; President | Executive Board | 2019 | 60 |
| Eric Hyllengren | Senior Vice President; Chief Financial Officer | Senior Management | 2023 | 48 |
| Amar Murugan | Executive Vice President; Chief Legal Officer | Senior Management | 2023 | 48 |
| Amie Krause | Chief People Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward